Email this article A case of delayed initial response to combination ipilimumab and nivolumab in malignant pleural mesothelioma
Vol 8, Issue 2, 2024
VIEWS - 10 (Abstract) 2 (PDF)
Abstract
Malignant pleural mesothelioma has a poor prognosis with limited therapeutic options Although numerous trials have shown that combination immunotherapy with nivolumab and ipilimumab is one of the first line treatments for patients with unresectable MPM, there is limited data on delayed responses over a long follow up period. We report a case of a delayed response 7 months after the cessation of immunotherapy in a patient who initially had progressive malignant pleural mesothelioma with metastases.
Keywords
Full Text:
PDFReferences
1. Munot MN, Utpat KV, Desai UD, et al. Malignant mesothelioma-Report of two cases with different presentations. Indian Journal of Occupational and Environmental Medicine. 2019; 23(2): 93. doi: 10.4103/ijoem.IJOEM_237_18
2. Popat S, Baas P, Faivre-Finn C, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Annals of Oncology. 2022; 33(2): 129-142. doi: 10.1016/j.annonc.2021.11.005
3. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet. 2021; 397(10272): 375-86. doi: 10.1016/S0140-6736(20)32714-8
4. Mankor JM, Disselhorst MJ, Poncin M, et al. Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials. EBioMedicine. 2020; 62.
5. Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. The Lancet Oncology. 2019; 20(2): 239-53. doi: 10.1016/S1470-2045(18)30765-4
6. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review. Journal of Clinical Oncology. 1996; 14(3): 1007-1017. doi: 10.1200/jco.1996.14.3.1007
7. Tao AS. Systemic treatment for unresectable malignant pleural mesothelioma. Available online: https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma?search=treatment%2Bof%2Bmalignant%2Bpleural%2Bmesothelioma&source=search_result&selectedTitle=1~42&usage_type=default&display_rank=1 (accessed on 8 August 2023).
8. Perrino M, De Vincenzo F, Cordua N, et al. Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress. Frontiers in Immunology. 2023; 14: 1121557. doi: 10.3389/fimmu.2023.1121557
9. Lee CW, Murray N, Anderson H, et al. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer. 2009; 64(3):308-13.
10. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III Study of Pemetrexed in Combination with Cisplatin Versus Cisplatin Alone in Patients with Malignant Pleural Mesothelioma. Journal of Clinical Oncology. 2023; 41(12): 2125-2133. doi: 10.1200/jco.22.02542
11. Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Annals of Oncology. 2022; 33(5): 488-499. doi: 10.1016/j.annonc.2022.01.074
12. Jones RG, Karthik F, Dugar A, et al. Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes. American Journal of Case Reports. 2018; 19: 783-789. doi: 10.12659/ajcr.909584
13. Fennell D, Ottensmeier C, Califano R, et al. PS01.11 Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial. Journal of Thoracic Oncology. 2021; 16(3): S62. doi: 10.1016/j.jtho.2021.01.323
14. Quispel-Janssen J, van der Noort V, de Vries JF, et al. Programmed Death 1 Blockade with Nivolumab in Patients with Recurrent Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 2018; 13(10): 1569-1576. doi: 10.1016/j.jtho.2018.05.038
15. Disselhorst MJ, Quispel-Janssen J, Lalezari F, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. The Lancet Respiratory Medicine. 2019; 7(3): 260-70. doi: 10.1016/S2213-2600(18)30420-X
16. Spatola C, Militello C, Tocco A, et al. Intensity-Modulated Radiotherapy for Relapsed Malignant Pleural Mesothelioma. Future Oncology. 2016; 12(sup23): 67-71. doi: 10.2217/fon-2016-0330
17. Spatola C, Militello C, Tocco A, et al. Single-Institution Experience of Intensity-Modulated Radiotherapy for Malignant Pleural Mesothelioma at University of Catania. Future Oncology. 2018; 14(sup6): 17-21. doi: 10.2217/fon-2017-0280
18. Guan Y, Feng D, Yin B, et al. Immune-related dissociated response as a specific atypical response pattern in solid tumors with immune checkpoint blockade. Therapeutic Advances in Medical Oncology. 2022; 14. doi: 10.1177/17588359221096877
19. Bernard-Tessier A, Baldini C, Castanon E, et al. Patterns of progression in patients treated for immuno-oncology antibodies combination. Cancer Immunology, Immunotherapy. 2020; 70(1): 221-232. doi: 10.1007/s00262-020-02647-z
20. Wong A, Vellayappan B, Cheng L, et al. Atypical Response Patterns in Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors—Navigating the Radiologic Potpourri. Cancers. 2021; 13(7): 1689. doi: 10.3390/cancers13071689
DOI: https://doi.org/10.24294/ti8705
Refbacks
- There are currently no refbacks.
Copyright (c) 2024 Chamodi Pillippu Hewa, Yasir Khan
License URL: https://creativecommons.org/licenses/by/4.0/
This site is licensed under a Creative Commons Attribution 4.0 International License.